Project Grant HT94252510524
Award Date
8/1/25
Completion Date
7/31/28
Dollars Obligated
$1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Tacoma, WA 98402, USA
Similar Awards
This Project Grant award for $366,000.00, awarded on Sep 30, 2024 by the Defense Health Agency, supports research conducted by The Geneva Foundation to identify functional structural variants that influence therapy outcomes for human castration-resistant prostate cancer. The award is funded through the Military Medical Research and Development program (CFDA 12.420), which supports a broad range of biomedical research initiatives to improve health outcomes for military service members,...
The U.S. Department of Defense's Defense Health Agency awarded a $488,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Geneva Foundation, a non-profit organization. The grant, awarded on July 1, 2024, supports research to investigate novel mechanisms of regulating the PAX3-FOXO1 fusion oncogene in rhabdomyosarcoma, a type of soft tissue cancer. The research aims to advance treatments for this rare and aggressive form of cancer, with a projected...
The Geneva Foundation was awarded a $1,597,740 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from June 2022 to June 2026 to develop new methods for accessing extracellular vesicle MDM2 DNA cargo as a potential liposarcoma biomarker. Through support of basic, applied, and advanced biomedical research, the Military Medical Research and Development program aims to transform...
The federal Project Grant award for $909,510.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports The Geneva Foundation's research initiative "PRECISION THERAPY FOR THE ERADICATION OF BRAIN METASTATIC BREAST CANCER". The project aims to develop innovative treatment approaches for brain metastases associated with breast cancer, with a focus on translational research and clinical trials. The 3-year project,...
The Geneva Foundation received a $453,029 Project Grant award from the Department of the Army Medical Command on February 1, 2021 to improve the therapeutic index of antibody drug conjugates targeting metastatic breast cancer. Funded through January 31, 2024 under the Military Medical Research and Development program (CFDA 12.420), this award will support the Foundation's work to transform healthcare and investigate medical solutions for the battlefield by developing more effective targeted...
The Geneva Foundation was awarded a $362,100 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program to conduct research toward the dual targeting of HER2 and androgen receptor in patients with high-risk, hormone-naive prostate cancer with curative intent. The two-year grant project period runs from June 1, 2022 to May 31, 2024. Through this funding, The Geneva Foundation will perform applied medical research investigating...
This federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $1,065,392.00 to The Geneva Foundation to conduct research on "LOCAL SLEEP IN THE WAKING BRAIN: A NOVEL TARGET FOR COGNITIVE FATIGUE". The project period runs from June 1, 2024 to May 31, 2028. As a non-profit research organization, The Geneva Foundation will perform foundational biomedical research investigating innovative treatments for...
The Defense Health Agency awarded a $168,200 Project Grant to Health Research, Inc. Roswell Park Division under the Military Medical Research and Development program (CFDA 12.420) to investigate alternative polyadenylation as a mediator of therapeutic resistance in lung cancer. The two-year award beginning July 1, 2021 will support research into innovative medical solutions for lung cancer treatment through the study of alternative polyadenylation, a novel area of investigation that could help...
The federal Project Grant award of $876,686.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research by Cedars-Sinai Medical Center to unravel genomic rearrangements in epidermal growth factor (EGF)-mutant non-small cell lung cancer (NSCLC) and investigate mechanisms underlying resistance to tyrosine kinase inhibitors. This 3-year research project, commencing on May 15, 2025 and concluding on May 14, 2028, aims to...
The Geneva Foundation received a $4,676,544 Project Grant award from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) to develop and validate innate immunome-targeted therapies to create a pro-survival and organ-protective phenotype after hemorrhage at the point of injury. Specifically, the Foundation will investigate immunotherapy approaches for hemorrhage treatments using innate immunome-targeted therapies from July 1, 2023 to...